Natera Acquires Foresight Diagnostics in $450 Million Deal
Transaction expands Natera's solid tumor MRD capabilities and adds ultrasensitive phased variant technology with detection below 0.1 parts per million.
Tag: Natera
All
Latest
All
Latest
Prospera Kidney dd-cfDNA Test Effectively Predicts Antibody Mediated Rejection, Study Shows
Investigators found that in predicting AMR, dd-cfDNA testing with the Prospera Kidney test was superior to the current standard of care.
All
Latest
Study Supports Tumor-Informed Blood Test as a Predictor of Cancer Survival
Study results support use of the blood test as a surrogate endpoint in clinical trials to assess the effectiveness of immune checkpoint inhibitors.
Natera Chosen for Circulating Tumor DNA Study in Breast Cancer
Natera is collaborating with Imperial College London and the University of Leicester to evaluate use of the company’s Signatera research-use-only personalized ctDNA technology for detecting disease recurrence among women breast cancer patients.
Read More